Glaucoma News

With the year winding down, many of us are reviewing the numbers for 2019, looking for Section 179 purchase items for this tax year and planning for the new year of the optometrist, 2020.

In March, the FDA approved Aerie Pharmaceuticals’ netarsudil and latanoprost compound for the treatment of glaucoma and ocular hypertension. The news was the most-read glaucoma article on Healio/OSN in 2019.

The FDA has approved an abbreviated new drug application for travoprost ophthalmic solution 0.004%, Alembic Pharmaceuticals announced in a press release.

ORLANDO, Fla. – Artificial intelligence can reliably detect the glaucomatous disc; however, it is not yet FDA approved for use in clinical management due to the lack of biomarkers, Louis R. Pasquale, MD, FARVO, said here at the Optometric Glaucoma Society meeting, held prior to the American Academy of Optometry meeting.

by Michael S. Jaffee, MD, FAAN, FANA

ORLANDO, Fla. – The growing incidence of myopia will be associated with an increased risk of retinal conditions, and patients should be educated on the signs and symptoms, Judy E. Kim, MD, said.

NEW YORK — In his presentation at OSN New York 2019, Nathan Radcliffe, MD, discusses monitoring endothelial cell loss in glaucoma surgery patients, including those who have received the CyPass (Alcon) and Hydrus (Ivantis) devices.

In eyes with open-angle glaucoma, endothelial cell loss after phacoemulsification combined with CyPass implantation continued for at least 5 years, while endothelial cell loss stabilized in eyes that underwent phaco without CyPass implantation after 3 months, according to a study.

Aerie Pharmaceuticals has submitted a marketing authorization application for Roclanda to the European Medicines Agency, according to a press release.

ORLANDO, Fla. – Medications can impact the ocular surface whether or not they contain preservatives, according to Rich Mangan, OD, FAAO; Mitch Ibach, OD, FAAO; and Scott Hauswirth, OD, FAAO, here at the American Academy of Optometry meeting.